Comments
Sun Pharmaceutical will acquire Ocular Technologies, Sarl (OTS) from a portfolio company of Auven Therapeutics, an international private equity company focused on therapeutic drugs.
OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution). Sun Pharma will pay Auven $ 40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on sales of Seciera.
Seciera is currently in a Phase-3 confirmatory clinical trial for the treatment of dry eye disease.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.